Starfighters and Vaya to Collaborate on Air-Launch and Captive Carry Projects

Starfighters Space (FJET) and Vaya Defense & Space, a privately held company, signed a memorandum of understanding to collaborate on supersonic captive-carry flight testing and air-launch propulsion. They will evaluate Vaya's Vortex-Hybrid engine for Starfighters' STARLAUNCH® system and explore flying hypersonic test articles aboard Starfighters' Wind Tunnel in the Sky® service. Both companies are located on Florida's Space Coast.

Original reporting
Published Sep 9, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Starfighters and Vaya to Collaborate on Air-Launch and Captive Carry Projects — source image
Decision brief

The 30-second read

$FJETNeutralLow
01

Why it matters

The collaboration aims to test hybrid propulsion in flight, potentially expanding Starfighters' service portfolio and creating a new market for hybrid rockets.

02

Market read

A niche partnership that could modestly enhance Starfighters' capabilities; limited immediate trading impact.

03

What to watch

No disclosed financial commitment; Vaya's private status adds execution risk.

Relevance 5/10Novelty 5/10Timing: announcement today

Background

Starfighters operates a fleet of F‑104 aircraft for supersonic air‑launch services. Vaya develops a patented Vortex‑Hybrid rocket engine.

Company-level read

Ticker impact

$FJETNeutralMedium confidence
Context

Starfighters announced a new MOU with Vaya to evaluate hybrid rocket engines for its air‑launch system and captive‑carry tests.

Expected impact

Modest upside if market views the partnership as a growth catalyst; limited downside risk.

Evidence & confidence

The MOU is an early‑stage collaboration without disclosed financial terms; impact depends on successful engine integration.

Market effects

May signal increased activity in the commercial hypersonic test‑flight niche, potentially benefiting other air‑launch service providers.

Focused on Florida's Space Coast aerospace cluster; limited broader regional effect.

Limited to niche aerospace segment; unlikely to move broader markets.

Counterpoint

The partnership could be a distraction if integration challenges delay existing contracts, weighing on the stock.

Key entities

  • Starfighters Space, Inc.

    Operator of commercial Mach 2+ air‑launch aircraft (NYSE American: FJET).

  • Vaya Defense & Space, Inc.

    Privately held developer of hybrid rocket engines.

Related articles

$FJETMed

EXCLUSIVE: FAA Wants America to Go Supersonic Again — FJET CEO Says New Rules Are a ‘Positive Signal,’ Bu

The FAA proposed new rules allowing supersonic flight over land if sonic-boom overpressure stays below 0.11 PSF. Starfighters Space (FJET) CEO Tim Franta sees this as a positive signal for the industry. Boom Supersonic has demonstrated a boom-mitigation approach, but faces challenges in certification and economics. Analysts highlight financing and certification progress as critical factors for investors.

$RKLBMedAI 8/10

Hypersonic Technology Market Projected to Reach $15.73 Billion by 2030, and Flight Test Time Has Become the Bottleneck

The global hypersonic technology market is projected to grow to $15.73B by 2030, with a 13.2% CAGR. Key players include Starfighters Space (FJET), Rocket Lab (RKLB), Kratos (KTOS), L3Harris (LHX), and Karman (KRMN). Starfighters entered an MOU with Vaya Defense to explore air-launch propulsion and testing, addressing constraints in hypersonic flight testing.

$FJETMedAI 8/10

Starfighters Space (NYSE: FJET) Added to Membership of Russell 3000® Index

Starfighters Space (NYSE: FJET) said it was added to the Russell 3000 Index, effective when U.S. markets open June 29, 2026, following the first 2026 Russell reconstitution. The June review ranks up to 4,000 U.S. stocks by market cap as of April 30. Russell 3000 membership also brings inclusion in Russell 1000/2000 and related style indexes, expanding institutional visibility.

$FJETMedAI 8/10

Capital Floods Into Space Stocks As STARLAUNCH And Hypersonic Programs Move Toward Commercial Scale

The article says capital is flowing into U.S.-listed space companies as SpaceX prepares its Nasdaq IPO. It cites Space Foundation data: the space economy nears $613B in 2024 and may exceed $1T by 2032. Starfighters (FJET) announced a $17.5M equity investment to advance STARLAUNCH, targeting a demo flight in 18–24 months. It also lists contract/backlog updates for Rocket Lab, Intuitive Machines, and Firefly.

$GKOSMedAI 8/10

Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study

Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.

$ADXNMedAI 8/10

Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Addex Therapeutics (ADXN) announced its spin-out, Neurosterix, completed Phase 1 trials for NTX-253, a schizophrenia treatment. Neurosterix plans to advance NTX-253 to Phase 2. Addex holds a 20% stake in Neurosterix, which raised $65M in Series A funding. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, showing promising preclinical results.